European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 1.72% to 1,721.10 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed 7.6% and 4.4% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and biopharmaceutical company Grifols (GRFS), which advanced 3.9% and 3.6% respectively.

The only decliners from continental Europe were biotech firm Evaxion (EVAX) and consumer goods company Unilever (UL), which fell 5.8% and 5.5% respectively.

The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which rose 10% and 6% respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and Bicycle Therapeutics (BCYC), which were up 5.3% and 4.8% respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 4.2% and 1.1% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biopharmaceutical company Akari Therapeutics (AKTX), which were down 0.9% and 0.8% respectively.